Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan

Yuji Ikeda, Akiko Furusawa, Ryo Kitagawa, Aya Tokinaga, Fuminori Ito, Masayo Ukita, Hidetaka Nomura, Wataru Yamagami, Hiroshi Tanabe, Mikio Mikami, Nobuhiro Takeshima, Nobuo Yaegashi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Although radiation therapy (RT) and concurrent chemoradiotherapy (CCRT) are the global standards for adjuvant therapy treatment in cervical cancer, many Japanese institutions choose chemotherapy (CT) because of the low frequency of irreversible adverse events. In this study, we aimed to clarify the trends of adjuvant therapy for intermediate/highrisk cervical cancer after radical surgery in Japan. Methods: A questionnaire survey was conducted by the Japanese Gynecologic Oncology Group to 186 authorized institutions active in the treatment of gynecologic cancer. Results: Responses were obtained from 129 facilities. Adjuvant RT/CCRT and intensitymodulated RT were performed in 98 (76%) and 23 (18%) institutions, respectively. On the other hand, CT was chosen as an alternative in 93 institutions (72%). The most common regimen of CT, which was used in 66 institutions (51%), was a combination of cisplatin/ carboplatin with paclitaxel. CT was considered an appropriate alternative option to RT/CCRT in patients with risk factors such as bulky tumors, lymph node metastasis, lymphovascular invasion, parametrial invasion, and stromal invasion. The risk of severe adverse events was considered to be lower for CT than for RT/CCRT in 109 institutions (84%). Conclusion: This survey revealed a variety of policies regarding adjuvant therapy among institutions. A clinical study to assess the efficacy or non-inferiority of adjuvant CT is warranted.

Original languageEnglish
Article numbere29
JournalJournal of Gynecologic Oncology
Volume27
Issue number3
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Uterine Cervical Neoplasms
Chemoradiotherapy
Japan
Radiotherapy
Recurrence
Drug Therapy
Therapeutics
Carboplatin
Adjuvant Chemotherapy
Paclitaxel
Cisplatin
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Surveys and Questionnaires

Keywords

  • Adjuvant therapy
  • Drug therapy
  • Radiation
  • Uterine cervical neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan. / Ikeda, Yuji; Furusawa, Akiko; Kitagawa, Ryo; Tokinaga, Aya; Ito, Fuminori; Ukita, Masayo; Nomura, Hidetaka; Yamagami, Wataru; Tanabe, Hiroshi; Mikami, Mikio; Takeshima, Nobuhiro; Yaegashi, Nobuo.

In: Journal of Gynecologic Oncology, Vol. 27, No. 3, e29, 01.05.2016.

Research output: Contribution to journalArticle

Ikeda, Y, Furusawa, A, Kitagawa, R, Tokinaga, A, Ito, F, Ukita, M, Nomura, H, Yamagami, W, Tanabe, H, Mikami, M, Takeshima, N & Yaegashi, N 2016, 'Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan', Journal of Gynecologic Oncology, vol. 27, no. 3, e29. https://doi.org/10.3802/jgo.2016.27.e29
Ikeda, Yuji ; Furusawa, Akiko ; Kitagawa, Ryo ; Tokinaga, Aya ; Ito, Fuminori ; Ukita, Masayo ; Nomura, Hidetaka ; Yamagami, Wataru ; Tanabe, Hiroshi ; Mikami, Mikio ; Takeshima, Nobuhiro ; Yaegashi, Nobuo. / Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan. In: Journal of Gynecologic Oncology. 2016 ; Vol. 27, No. 3.
@article{db85f22b0eed4c09b1ea45a6ee0fb365,
title = "Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan",
abstract = "Objective: Although radiation therapy (RT) and concurrent chemoradiotherapy (CCRT) are the global standards for adjuvant therapy treatment in cervical cancer, many Japanese institutions choose chemotherapy (CT) because of the low frequency of irreversible adverse events. In this study, we aimed to clarify the trends of adjuvant therapy for intermediate/highrisk cervical cancer after radical surgery in Japan. Methods: A questionnaire survey was conducted by the Japanese Gynecologic Oncology Group to 186 authorized institutions active in the treatment of gynecologic cancer. Results: Responses were obtained from 129 facilities. Adjuvant RT/CCRT and intensitymodulated RT were performed in 98 (76{\%}) and 23 (18{\%}) institutions, respectively. On the other hand, CT was chosen as an alternative in 93 institutions (72{\%}). The most common regimen of CT, which was used in 66 institutions (51{\%}), was a combination of cisplatin/ carboplatin with paclitaxel. CT was considered an appropriate alternative option to RT/CCRT in patients with risk factors such as bulky tumors, lymph node metastasis, lymphovascular invasion, parametrial invasion, and stromal invasion. The risk of severe adverse events was considered to be lower for CT than for RT/CCRT in 109 institutions (84{\%}). Conclusion: This survey revealed a variety of policies regarding adjuvant therapy among institutions. A clinical study to assess the efficacy or non-inferiority of adjuvant CT is warranted.",
keywords = "Adjuvant therapy, Drug therapy, Radiation, Uterine cervical neoplasms",
author = "Yuji Ikeda and Akiko Furusawa and Ryo Kitagawa and Aya Tokinaga and Fuminori Ito and Masayo Ukita and Hidetaka Nomura and Wataru Yamagami and Hiroshi Tanabe and Mikio Mikami and Nobuhiro Takeshima and Nobuo Yaegashi",
year = "2016",
month = "5",
day = "1",
doi = "10.3802/jgo.2016.27.e29",
language = "English",
volume = "27",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "3",

}

TY - JOUR

T1 - Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan

AU - Ikeda, Yuji

AU - Furusawa, Akiko

AU - Kitagawa, Ryo

AU - Tokinaga, Aya

AU - Ito, Fuminori

AU - Ukita, Masayo

AU - Nomura, Hidetaka

AU - Yamagami, Wataru

AU - Tanabe, Hiroshi

AU - Mikami, Mikio

AU - Takeshima, Nobuhiro

AU - Yaegashi, Nobuo

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective: Although radiation therapy (RT) and concurrent chemoradiotherapy (CCRT) are the global standards for adjuvant therapy treatment in cervical cancer, many Japanese institutions choose chemotherapy (CT) because of the low frequency of irreversible adverse events. In this study, we aimed to clarify the trends of adjuvant therapy for intermediate/highrisk cervical cancer after radical surgery in Japan. Methods: A questionnaire survey was conducted by the Japanese Gynecologic Oncology Group to 186 authorized institutions active in the treatment of gynecologic cancer. Results: Responses were obtained from 129 facilities. Adjuvant RT/CCRT and intensitymodulated RT were performed in 98 (76%) and 23 (18%) institutions, respectively. On the other hand, CT was chosen as an alternative in 93 institutions (72%). The most common regimen of CT, which was used in 66 institutions (51%), was a combination of cisplatin/ carboplatin with paclitaxel. CT was considered an appropriate alternative option to RT/CCRT in patients with risk factors such as bulky tumors, lymph node metastasis, lymphovascular invasion, parametrial invasion, and stromal invasion. The risk of severe adverse events was considered to be lower for CT than for RT/CCRT in 109 institutions (84%). Conclusion: This survey revealed a variety of policies regarding adjuvant therapy among institutions. A clinical study to assess the efficacy or non-inferiority of adjuvant CT is warranted.

AB - Objective: Although radiation therapy (RT) and concurrent chemoradiotherapy (CCRT) are the global standards for adjuvant therapy treatment in cervical cancer, many Japanese institutions choose chemotherapy (CT) because of the low frequency of irreversible adverse events. In this study, we aimed to clarify the trends of adjuvant therapy for intermediate/highrisk cervical cancer after radical surgery in Japan. Methods: A questionnaire survey was conducted by the Japanese Gynecologic Oncology Group to 186 authorized institutions active in the treatment of gynecologic cancer. Results: Responses were obtained from 129 facilities. Adjuvant RT/CCRT and intensitymodulated RT were performed in 98 (76%) and 23 (18%) institutions, respectively. On the other hand, CT was chosen as an alternative in 93 institutions (72%). The most common regimen of CT, which was used in 66 institutions (51%), was a combination of cisplatin/ carboplatin with paclitaxel. CT was considered an appropriate alternative option to RT/CCRT in patients with risk factors such as bulky tumors, lymph node metastasis, lymphovascular invasion, parametrial invasion, and stromal invasion. The risk of severe adverse events was considered to be lower for CT than for RT/CCRT in 109 institutions (84%). Conclusion: This survey revealed a variety of policies regarding adjuvant therapy among institutions. A clinical study to assess the efficacy or non-inferiority of adjuvant CT is warranted.

KW - Adjuvant therapy

KW - Drug therapy

KW - Radiation

KW - Uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84962407462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962407462&partnerID=8YFLogxK

U2 - 10.3802/jgo.2016.27.e29

DO - 10.3802/jgo.2016.27.e29

M3 - Article

C2 - 27029750

AN - SCOPUS:84962407462

VL - 27

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 3

M1 - e29

ER -